2021
DOI: 10.1016/j.jmb.2021.167276
|View full text |Cite
|
Sign up to set email alerts
|

Split Chloramphenicol Acetyl-Transferase Assay Reveals Self-Ubiquitylation-Dependent Regulation of UBE3B

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
1

Relationship

3
1

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 62 publications
0
2
0
Order By: Relevance
“…Targeted protein degradation represents an emerging therapeutic modality with the potential to tackle disease-causing proteins that have in the past been highly challenging to target with conventional small molecules. Our results pave the way for the development of CRL4 DCAF1 -dependent PROTACs or molecular glue degraders (Bekes et al, 2022; Levin-Kravets et al, 2021) to target PLK4 degradation as a novel modality for cancer therapy.…”
Section: Discussionmentioning
confidence: 82%
“…Targeted protein degradation represents an emerging therapeutic modality with the potential to tackle disease-causing proteins that have in the past been highly challenging to target with conventional small molecules. Our results pave the way for the development of CRL4 DCAF1 -dependent PROTACs or molecular glue degraders (Bekes et al, 2022; Levin-Kravets et al, 2021) to target PLK4 degradation as a novel modality for cancer therapy.…”
Section: Discussionmentioning
confidence: 82%
“…Targeted protein degradation represents an emerging therapeutic modality with the potential to tackle disease-causing proteins that have in the past been highly challenging to target with conventional small molecules. Our results pave the way for the development of CRL4 DCAF1 -dependent PROTACs or molecular glue degraders (Levin-Kravets et al, 2021;Bekes et al, 2022) to target PLK4 degradation as a novel modality for cancer therapy.…”
Section: Discussionmentioning
confidence: 82%
“…To validate the prediction models, we assessed the ability of the GAP domain of RASA1 to bind ubiquitin. Using a bacterial Split-Chloramphenicol Acetyl Transferase (Split-CAT) assay (Levin-Kravets et al, 2021 ), we detected the binding of wt-RASA1 GAP to ubiquitin, whereas E1015A/ R1016A mutations impaired ubiquitin binding (Fig. 3B ).…”
Section: Resultsmentioning
confidence: 95%
“…The assays were performed as previously described in (Levin-Kravets et al, 2021 ). E. coli Mach1 was co-transformed with pC-CAT-Ubiquitin and pN-CAT-RASA1 GAP or pN-CAT-NF1 GRD vectors and selected on agar plates supplemented with 30 μg/ml kanamycin and 25 μg/ml streptomycin respectively.…”
Section: Methodsmentioning
confidence: 99%